It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.
Here’s a table showing how ASX-listed healthcare stocks have been performing.
| Code | Name | Price | % Six Months | % Month | % Week | Market Cap |
|---|---|---|---|---|---|---|
| NEU | Neuren Pharmaceut. | 3.2 | 146 | 81 | 78 | $ 409,388,447.00 |
| ALT | Analytica Limited | 0.002 | -33 | 0 | 33 | $ 9,227,602.26 |
| CMP | Compumedics Limited | 0.395 | 7 | 4 | 16 | $ 63,778,661.28 |
| BXN | Bioxyne Ltd | 0.025 | 32 | -14 | 14 | $ 16,003,634.95 |
| OCC | Orthocell Limited | 0.575 | 0 | 14 | 12 | $ 100,086,033.18 |
| AMT | Allegra Orthopaedics | 0.17 | -32 | -19 | 10 | $ 17,758,064.51 |
| RHT | Resonance Health | 0.115 | -39 | 5 | 10 | $ 52,997,977.82 |
| RCE | Recce Pharmaceutical | 0.93 | -15 | -2 | 9 | $ 162,491,636.95 |
| ADR | Adherium Ltd | 0.012 | -33 | 0 | 9 | $ 26,444,034.49 |
| TLX | Telix Pharmaceutical | 7.16 | 55 | -2 | 8 | $ 1,967,003,065.20 |
| MVP | Medical Developments | 5.2 | 9 | 3 | 8 | $ 362,102,689.56 |
| EYE | Nova EYE Medical Ltd | 0.34 | 11 | -16 | 6 | $ 43,666,137.30 |
| SOM | SomnoMed Limited | 2.32 | -6 | -6 | 6 | $ 192,001,610.80 |
| RNO | Rhinomed Ltd | 0.29 | 93 | 0 | 5 | $ 69,797,511.30 |
| PXS | Pharmaxis Ltd | 0.105 | 31 | -13 | 5 | $ 53,572,722.37 |
| ACR | Acrux Limited | 0.105 | -25 | -13 | 5 | $ 28,368,033.80 |
| TSN | The Sust Nutri Grp | 0.245 | -44 | 7 | 4 | $ 24,276,596.25 |
| RGS | Regeneus Ltd | 0.074 | -14 | 6 | 4 | $ 22,063,457.81 |
| ONE | Oneview Healthcare | 0.25 | -38 | -31 | 4 | $ 118,143,984.60 |
| TRP | Tissue Repair | 0.53 | 4 | $ 22,365,155.80 | ||
| VLS | Vita Life Sciences.. | 1.75 | 48 | -6 | 3 | $ 92,142,071.00 |
| HXL | Hexima | 0.35 | 112 | -3 | 3 | $ 52,796,578.68 |
| ATX | Amplia Therapeutics | 0.18 | -24 | -7 | 3 | $ 27,918,187.38 |
| CGS | Cogstate Ltd | 2.3 | 149 | 5 | 2 | $ 405,613,910.40 |
| CAN | Cann Group Ltd | 0.29 | -30 | 2 | 2 | $ 99,423,533.36 |
| PGC | Paragon Care Limited | 0.305 | 5 | 0 | 2 | $ 107,177,213.20 |
| CAJ | Capitol Health | 0.36 | 1 | 9 | 1 | $ 362,634,129.20 |
| PBP | Probiotec Limited | 2.15 | 8 | 1 | 0 | $ 175,658,556.96 |
| BDX | Bcaldiagnostics | 0.13 | -13 | 0 | $ 17,098,453.06 | |
| SCU | Stemcell United Ltd | 0.014 | -18 | 0 | 0 | $ 14,606,489.21 |
| ONT | 1300 Smiles Limited | 7.13001 | 18 | 1 | 0 | $ 168,827,114.70 |
| MMJ | MMJ Group Hlds Ltd | 0.066 | -22 | -6 | 0 | $ 15,176,963.01 |
| MEB | Medibio Limited | 0.007 | -7 | -13 | 0 | $ 12,565,430.49 |
| IRX | Inhalerx Limited | 0.09 | -5 | -10 | 0 | $ 15,162,026.13 |
| JTL | Jayex Technology Ltd | 0.021 | -32 | -9 | 0 | $ 5,233,799.32 |
| IVX | Invion Ltd | 0.018 | 13 | -22 | 0 | $ 115,384,745.32 |
| IPD | Impedimed Limited | 0.17 | 42 | -6 | 0 | $ 301,888,125.34 |
| IMM | Immutep Ltd | 0.475 | -27 | -29 | 0 | $ 397,167,102.47 |
| ICS | ICSGlobal Limited | 0.575313 | 1 | 0 | 0 | $ 6,054,604.94 |
| FFC | Farmaforce Ltd | 0.046 | -34 | -10 | 0 | $ 6,011,325.08 |
| CDY | Cellmid Limited | 0.056 | -15 | -10 | 0 | $ 12,552,394.37 |
| CDX | Cardiex Limited | 0.052 | -36 | -17 | 0 | $ 56,237,825.60 |
| BOT | Botanix Pharma Ltd | 0.056 | -18 | -13 | 0 | $ 52,549,672.00 |
| AVE | Avecho Biotech Ltd | 0.015 | -17 | -17 | 0 | $ 23,869,514.84 |
| AHKDB | Ark Mines Limited | 0.034 | 0 | 0 | 0 | $ 88,946.01 |
| AHC | Austco Healthcare | 0.13 | 30 | -10 | 0 | $ 36,944,563.63 |
| AGH | Althea Group | 0.235 | -31 | -16 | 0 | $ 74,983,445.52 |
| AC8 | Auscann Grp Hlgs Ltd | 0.083 | -28 | -14 | 0 | $ 36,345,136.58 |
| MVF | Monash IVF Group Ltd | 0.92 | 5 | -5 | -1 | $ 354,567,704.40 |
| PIQ | Proteomics Int Lab | 1.18 | 11 | 13 | -1 | $ 122,560,815.00 |
| GSS | Genetic Signatures | 1.3 | 7 | -2 | -1 | $ 181,732,232.42 |
| BWX | BWX Limited | 4.3 | -16 | -10 | -1 | $ 672,512,354.14 |
| RAC | Race Oncology Ltd | 3.27 | -13 | -5 | -1 | $ 468,075,167.66 |
| TRU | Truscreen | 0.069 | -3 | -14 | -1 | $ 24,674,905.20 |
| PNV | Polynovo Limited | 1.435 | -45 | -18 | -2 | $ 975,547,364.90 |
| HCT | Holista CollTech Ltd | 0.05 | -18 | -12 | -2 | $ 13,767,454.35 |
| EZZ | EZZ Life Science | 0.46 | 6 | -6 | -2 | $ 5,400,000.00 |
| PAB | Patrys Limited | 0.037 | 24 | 0 | -3 | $ 74,042,010.32 |
| CTE | Cryosite Limited | 0.35 | -3 | -1 | -3 | $ 17,083,347.05 |
| OPT | Opthea Limited | 1.16 | -21 | -7 | -3 | $ 403,867,672.00 |
| PAA | Pharmaust Limited | 0.095 | -3 | -14 | -3 | $ 29,472,851.62 |
| MX1 | Micro-X Limited | 0.29 | -12 | -5 | -3 | $ 124,234,491.15 |
| PYC | PYC Therapeutics | 0.14 | -24 | -3 | -3 | $ 445,329,654.42 |
| ILA | Island Pharma | 0.27 | -25 | -10 | -4 | $ 11,675,654.82 |
| BNO | Bionomics Limited | 0.125 | -34 | 9 | -4 | $ 122,111,609.28 |
| M7T | Mach7 Tech Limited | 0.85 | -21 | -1 | -4 | $ 199,320,282.00 |
| PSQ | Pacific Smiles Grp | 2.78 | 3 | -6 | -4 | $ 435,658,690.74 |
| MEM | Memphasys Ltd | 0.091 | 44 | 15 | -4 | $ 72,880,407.00 |
| RAD | Radiopharm | 0.34 | -4 | $ 40,250,109.48 | ||
| LBT | LBT Innovations | 0.09 | 10 | -10 | -4 | $ 23,996,558.61 |
| TD1 | Tali Digital Limited | 0.021 | -38 | -30 | -5 | $ 18,638,115.78 |
| NYR | Nyrada Inc. | 0.21 | -34 | -18 | -5 | $ 27,038,626.34 |
| NC6 | Nanollose Limited | 0.1 | 8 | -17 | -5 | $ 15,633,068.64 |
| MXC | Mgc Pharmaceuticals | 0.039 | -17 | -19 | -5 | $ 99,335,579.33 |
| NTI | Neurotech Intl | 0.058 | 7 | -6 | -5 | $ 37,649,616.80 |
| VTI | Vision Tech Inc | 0.85 | -35 | -14 | -5 | $ 20,681,062.50 |
| RSH | Respiri Limited | 0.056 | -36 | -2 | -5 | $ 43,370,447.40 |
| ADO | Anteotech Ltd | 0.185 | -31 | -10 | -5 | $ 355,327,990.56 |
| MDR | Medadvisor Limited | 0.365 | 22 | -4 | -5 | $ 137,793,290.73 |
| OIL | Optiscan Imaging | 0.175 | -44 | -19 | -5 | $ 111,273,408.36 |
| CHM | Chimeric Therapeutic | 0.255 | -15 | -19 | -6 | $ 57,298,101.64 |
| NXS | Next Science Limited | 1.17 | -37 | -5 | -6 | $ 238,558,560.35 |
| ALC | Alcidion Group Ltd | 0.32 | -26 | -14 | -6 | $ 335,382,096.64 |
| LDX | Lumos Diagnostics | 0.875 | 5 | -6 | $ 123,350,131.80 | |
| EXL | Elixinol Wellness | 0.078 | -44 | -14 | -6 | $ 25,588,805.26 |
| DXB | Dimerix Ltd | 0.23 | -6 | -6 | -6 | $ 73,800,943.18 |
| UBI | Universal Biosensors | 0.83 | 26 | 11 | -6 | $ 143,978,996.88 |
| PTX | Prescient Ltd | 0.225 | 36 | -20 | -6 | $ 136,211,190.78 |
| OVN | Oventus Medical Ltd | 0.09 | -23 | -18 | -6 | $ 21,030,208.55 |
| CPH | Creso Pharma Ltd | 0.09 | -44 | -33 | -6 | $ 108,730,054.80 |
| GLH | Global Health Ltd | 0.37 | -53 | -4 | -6 | $ 20,379,381.12 |
| MDC | Medlab Clinical Ltd | 0.145 | -26 | -22 | -6 | $ 49,615,472.30 |
| RHY | Rhythm Biosciences | 1.71 | 74 | -14 | -7 | $ 348,825,059.27 |
| NOX | Noxopharm Limited | 0.4 | -39 | -19 | -7 | $ 116,895,180.00 |
| VHT | Volpara Health Tech | 1.06 | -13 | -11 | -7 | $ 263,920,735.05 |
| CYC | Cyclopharm Limited | 1.68 | -40 | -13 | -7 | $ 158,737,199.10 |
| SDI | SDI Limited | 1.02 | 12 | 1 | -7 | $ 124,214,478.85 |
| ACW | Actinogen Medical | 0.12 | -23 | -31 | -8 | $ 220,631,275.75 |
| 1ST | 1St Group Ltd | 0.012 | -44 | -25 | -8 | $ 6,045,311.12 |
| CU6 | Clarity Pharma | 0.825 | -23 | -8 | $ 138,152,070.14 | |
| ARX | Aroa Biosurgery | 1.05 | -7 | -4 | -8 | $ 360,665,270.88 |
| ATH | Alterity Therap Ltd | 0.023 | -18 | -21 | -8 | $ 52,951,240.72 |
| ZLD | Zelira Therapeutics | 0.034 | -31 | -15 | -8 | $ 45,944,339.11 |
| IMC | Immuron Limited | 0.11 | -31 | -12 | -8 | $ 23,895,857.58 |
| GTG | Genetic Technologies | 0.0055 | -31 | -15 | -8 | $ 50,786,808.29 |
| CYP | Cynata Therapeutics | 0.48 | -17 | -19 | -9 | $ 71,638,297.00 |
| OSX | Osteopore Limited | 0.21 | -53 | -16 | -9 | $ 25,799,012.36 |
| EPN | Epsilon Healthcare | 0.105 | -34 | -13 | -9 | $ 20,234,229.65 |
| ZNO | Zoono Group Ltd | 0.36 | -51 | -17 | -9 | $ 61,165,701.59 |
| S66 | Star Combo | 0.255 | 9 | -27 | -9 | $ 34,351,679.60 |
| PAR | Paradigm Bio. | 1.9 | -11 | -21 | -10 | $ 441,535,842.30 |
| DVL | Dorsavi Ltd | 0.019 | -37 | -17 | -10 | $ 6,677,218.87 |
| BPH | BPH Energy Ltd | 0.037 | -57 | -31 | -10 | $ 24,602,017.39 |
| BIT | Biotron Limited | 0.083 | 63 | 69 | -10 | $ 52,644,953.48 |
| NSB | Neuroscientific | 0.32 | 5 | -10 | -10 | $ 45,910,925.76 |
| CBL | Control Bionics | 0.45 | -18 | -4 | -10 | $ 24,410,489.41 |
| BD1 | Bard1 Life Sciences | 1.035 | -45 | 1 | -10 | $ 94,319,165.45 |
| ALA | Arovella Therapeutic | 0.035 | -17 | -15 | -10 | $ 16,832,230.80 |
| VBS | Vectus Biosystems | 1.2 | 30 | -27 | -10 | $ 39,382,413.29 |
| OSL | Oncosil Medical | 0.04 | -35 | -13 | -11 | $ 31,693,731.76 |
| PAL | Palla Pharma Ltd | 0.345 | -14 | 3 | -12 | $ 61,527,001.94 |
| ICR | Intelicare Holdings | 0.088 | -61 | -18 | -12 | $ 4,306,183.20 |
| ANP | Antisense Therapeut. | 0.18 | -16 | -20 | -12 | $ 118,405,741.50 |
| RAP | Resapp Health Ltd | 0.057 | 12 | 10 | -12 | $ 48,974,233.39 |
| IMU | Imugene Limited | 0.48 | 30 | -19 | -13 | $ 2,763,075,336.96 |
| 1AD | Adalta Limited | 0.074 | -51 | -17 | -13 | $ 18,669,015.67 |
| IHL | Incannex Healthcare | 0.495 | 80 | -5 | -13 | $ 580,093,441.44 |
| OSP | Osprey Med Inc | 0.655 | -59 | -26 | -13 | $ 17,447,808.56 |
| 4DX | 4Dmedical Limited | 1.185 | -7 | -14 | -14 | $ 252,836,473.23 |
| IBX | Imagion Biosys Ltd | 0.075 | -35 | 6 | -14 | $ 81,834,352.98 |
| LCT | Living Cell Tech. | 0.006 | -48 | -22 | -14 | $ 6,882,439.80 |
| SHG | Singular Health | 0.26 | -20 | 11 | -15 | $ 17,790,707.55 |
| PCK | Painchek Ltd | 0.054 | -21 | 15 | -16 | $ 63,381,068.74 |
| DOC | Doctor Care Anywhere | 0.45 | -50 | -27 | -16 | $ 89,397,025.39 |
| KZA | Kazia Therapeutics | 1.17 | -6 | -25 | -17 | $ 157,074,367.67 |
| IDT | IDT Australia Ltd | 0.52 | 73 | 12 | -17 | $ 123,527,987.55 |
| AT1 | Atomo Diagnostics | 0.18 | 6 | -28 | -20 | $ 75,607,712.35 |
The biggest winner was Neuren Pharmaceuticals (ASX:NEU) up 78%, after announcing it’s close to launching the first ever drug for Rett syndrome to the market.
The company announced that its North American partner, Acadia Pharma (Nasdaq: ACAD) reported positive top-line results from the Phase 3 Lavender study of trofinetide, which means the $400m-capped Neuren now has the potential to earn material revenues to the tune of hundreds of millions if the drug gets approved by the FDA.
A Pre-New Drug Application meeting with the FDA is planned for Q1 2022, with the all important New Drug Application (NDA) slated for mid-year.
“We’ll be the first ever treatment that’s ever approved for Rett, and that’s groundbreaking,” CEO Jon Pilcher told Stockhead.
Analytica (ASX:ALT) was up 33% on no news, followed by Compumedics (ASX:CMP) up 16% after Victorian Minister for Industry Support and Recovery Martin Pakula announced that the company will manufacture its Somfit medical-grade wearable sleep monitoring device at its global headquarters in Abbotsford after a decade of manufacturing most of its products overseas.
The project will represent the first volume manufacturing of wearable medical-grade monitoring technology in Australia – creating 33 jobs in engineering, design and ICT in the state over three years.
Compumedics is targeting an estimated export market value of $60 million over five years.
Up 14% was Bioxyne (ASX:BXN), followed by Orthocell (ASX:OCC) which rose 12% after releasing study results which show its OrthoATI treatment is “significantly” more effective than steroid injection for the treatment of rotator cuff tendinopathy with intrasubstance tendon tear.
Allegra Orthopaedics (ASX:AMT) rose 10% on no news, with Resonance Health (ASX:RHT) also up 10% after submitting its LiverSmart AI medical device to the FDA for US regulatory clearance.
Who flatlined?
Flat was Immutep (ASX:IMM), which reported good safety from the first five patients in triple combination therapy EFTU study Insight-003.
The study will continue to recruit up to 20 patients with various solid tumours and additional results are expected in CY22.
Then there was Avecho Biotech (ASX:AVE), which released the results for its Australian Phase I PK study which characterises the absorption profile of cannabidiol from its CBD soft-gel product.
“We now understand the absorption profile from both doses of our proprietary CBD soft-gel in humans,” CEO Dr Paul Gavin said.
“The results are exciting and show that the delivery profiles from both doses could support utility across a range of potential indications, whether they require once per day, or twice per day, dosing.”
Who’s the biggest loser?
The biggest loser was Atomo Diagnostics (ASX:AT1), down 20% on no news.
Followed by IDT Australia (ASX:IDT), down 17%. The company recently announced it had successfully manufactured Australia’s first mRNA COVID-19 vaccine candidate.
The company said it has met all specifications and will provide the drugs to the Monash Institute of Pharmaceutical Sciences (MIPS), as part of its mRNA COVID-19 receptor binding domain vaccine clinical trial.
Also down 17% was oncology-focused company Kazia Therapeutics (ASX:KZA) which released positive final data from its Phase II clinical study of paxalisib for glioblastoma – with results confirming the previously reported safety and efficacy profile of the treatment.